A research report has alleged major safety violations by Genscript’s subsidiary, Nanjing Legend Biotech, that has partnered with Johnson & Johnson.
The report, from obscure research company, Flaming Research, alleged that Nanjing Legend Biotechnology (Legend operates in USA, Hong Kong, mainland China and Ireland) bypassed standard safety procedures while testing an experimental gene therapy on Chinese cancer patients. It accused parent company GenScript of cherry picking results disclosed to investors, according to WSJ.
China-based Genscript was pushed into the spotlight after Legend presented impressive results for its BCMA-targeting CAR-T at the 2017 American Society of Clinical Oncology (ASCO) meeting.
According to the Pharma Letter, Genscript is now consulting lawyers after what they say is a “misleading” CAR-T report.